Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill

Maurizio Guida  
Giuseppe Bifulco  
Attilio Di Spiezio Sardo  
Mariamaddalena Scala  
Loredana Maria Sosa Fernandez  
Carmine Nappi

Dipartimento di Scienze Obstetriche Ginecologiche Urologiche e Medicina della Riproduzione Umana, Università degli Studi “Federico II”, Napoli, Italia

Abstract: The aim of this review is to define the role of the combined dienogest (DNG)/estradiol valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological effects and clinical application as well. E2V is the esterified form of 17β-estradiol (E2), while dienogest is a fourth-generation progestin with a partial antiandrogenic effect. The cycle stability is achieved with 2 to 3 mg DNG, supporting contraceptive efficacy. In this new oral contraceptive, E2V is combined with DNG in a four-phasic dose regimen (the first two tablets contain 3 mg E2V; the next five tablets include 2 mg E2V + 2 mg DNG, followed by 17 tablets with 2 mg E2V + 3 mg DNG; followed by two tablets with 1 mg E2V only, and finally two placebo tablets). Duration and intensity of scheduled withdrawal bleeding are lower with this contraceptive pill, whereas the incidence and the intensity of intra-cyclic bleeding are similar to the other oral contraceptive. With this new pill the levels of high density lipoprotein increased, while the levels of prothrombin fragment 1 + 2 and D-dimer remained relatively unchanged; the levels of sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin increased. The most frequently reported adverse events are: breast pain, headache, acne, alopecia, migraine, increase of bodyweight. The satisfaction rate is about 79.4%.

Keywords: estradiol valerate, dienogest, combined oral contraceptive, four-phasic regimen, contraceptive safety

Introduction

Oral contraceptives were first approved for contraceptive use in the United States in 1960, and are a very popular form of birth control as well as a widely accepted method of contraception. They are currently used by more than 100 million women worldwide and by almost 12 million women in the United States. Despite their undoubted popularity, some women experience adverse events while taking oral contraceptives, including breast tenderness, headache, nausea and loss of libido. In addition, epidemiological studies have suggested an association between oral contraceptive use and an increased risk of arterial and venous thrombotic events.

In recent years, thanks to the availability of the new synthetic progestins as well as natural estrogens, new oral contraceptives showed high patient tolerance.

In May 2009, a new oral contraceptive became available in several European countries and in July 2009 Bayer submitted Qlaira® to the US Food and Drug Administration (FDA). Approval has been requested for two indications: oral contraception and treatment of menorrhagia and/or hypermenorrhea without organic pathology, in women desiring oral contraception.
In this oral contraceptive, estradiol valerate (E2V) is combined with the progestin dienogest (DNG) in a four-pha-
sic dose regimen, incorporating an estrogen step-down and a progestin step-up over 26 days, with two more placebo tablets, making up a treatment of up to 28 days (Figure 1). The first two tablets contain 3 mg E2V to prime the endo-
metrium. The next five tablets include 2 mg E2V and 2 mg DNG followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V only and two placebo tablets.3

A continuous intake for 28 days has a double purpose:
1. Optimization of the pharmacological profile, maintaining stable plasma hormone levels, and consequently reducing or eliminating catamenial symptoms (premenstrual symptoms, headache, dysmenorrhea), associated with decreasing estrogen levels, thus improving general well-
being.5
2. Improving adherence: the daily intake, without pauses, helps women to maintain a more regular intake, avoiding the frequent omission that may otherwise reduce contraceptive efficacy and increase adverse effects, such as intermenstrual spotting.5

The early estrogenic dominance guarantees the endome-
trial proliferation and sensitizes the tissue to the action of progestin, while progestogenic dominance in the middle and at the end of the cycle, followed by a moderate estrogenic activity in the final stage, ensure satisfactory endometrial sta-
bility. The brief 2-day interval without hormones has proved to be enough to ensure regular bleeding in most of the women under Qlaira® treatment, compared with the conventional association of ethinylestradiol (EE).6

The aim of this review was to define the role of the combined DNG/E2V contraceptive pill (Qlaira®; Bayer
Schering Pharma AG, Berlin, Germany) in terms of biochemistry, metabolic and pharmacological effects, and clinical application, referring to recently published oral contraceptives trial data, performed on women aged >18 and <50 years.

**Pharmacokinetic profile**

**E2V**

E2V (Figure 2) is the esterified form of 17β-estradiol (E2); it is rapidly and completely absorbed and hydrolyzed to natural estradiol (E2) during the first gastrointestinal tractpassage;6 E2V is almost identical to E2 in terms of pharmacokinetics, and exactly identical in pharmacodynamics and clinically; E2V releases E2, which is identical to the endogenously produced E2; 1 mg of E2V is equivalent to 0.76 mg of E2, based on molecular weight.7

**Absorption**

E2V is completely absorbed by the intestinal mucosa and cleav-
age to estradiol and valeric acid during first liver-passage.3

**Distribution**

Thirty-eight percent of E2 is bound to sex hormone binding globulin (SHBG), 60% to albumin, and 2% to 3% circulates in a free form (induction of SHBG to 150% during a 28-
daily cycle).4

The serum E2 concentration remains stable during the 28-day treatment period;4 the apparent volume of distribution is ~1.2 L/kg.3

**Metabolism**

Ninety-five percent is metabolized before entering the systemic circulation. Main metabolites are estrone, estrone sulfate and estrone glucuronide.4

---

**Figure 1** Dose regimen for Qlaira® (one cycle).
Abbreviations: DNG, dienogest; E2V, estradiol valerate.
Elimination
Terminal half-life is 13 to 20 hours due to enterohepatic recirculation and a large circulating pool of estrogen sulfates and glucuronides (90-min plasma half-life of circulating estradiol). Estradiol and its metabolites are predominately excreted in the urine. Minimal (~10%) excretion occurs via the feces.

DNG
DNG (Figure 3) has particular properties: it is similar to 19-nortestosterone derivatives (Figure 4) with a short plasma half-life (~11 hours), and has a strong progestational effect on the endometrium, high oral bioavailability (more that 90%); it is similar to progesterone derivatives with a relatively low inhibition of gonadotropin secretion, doses in milligram range, and anti-androgenic activity (40% of cyproterone acetate). Some specific properties of DNG are the absence of interaction with specific transport proteins (SHBG, cortisol binding globulin [CBG]), and a high concentration of the unbound substance in serum: 10% unbound, 90% bound to albumin.

Absorption
DNG is rapidly and almost completely absorbed with a bioavailability of ~90%.

Distribution
Ten percent of DNG is unbound, 90% is bound to albumin, with no binding to SHBG and CBG.

Metabolism
DNG is completely metabolized by cytochrome P450 3A4 (CYP3A4), hydroxylation and conjugation, mostly inactive metabolites. Unchanged DNG dominance is due to very quick excretion of metabolites.

Elimination
DNG plasma half-life is approximately 11 hours. Only 1% of the unchanged drug is excreted; urinary to fecal excretion ratio is 3:1, with 42% and 63% of an oral dose excreted renally within the first 24 hours and during the first 6 days. Approximately, 86% of a DNG dose is excreted via the urine or feces in 6 days. The pharmacologically inactive metabolites of DNG are rapidly excreted.

Concomitant administration of DNG and CYP3A4 inducers may result in elevated DNG clearance rates. Concurrent treatments with CYP3A4 inhibitors may elevate plasma DNG concentration.

The steady state is reached after 3 days which is not influenced by SHBG levels. There is no relevant accumulation.

Pharmacodynamic profile
E2 is considered weaker than EE in terms of hepatic protein synthesis induction, as demonstrated in clinical studies assessing SHBG, angiotensinogen and hemostatic parameters.

The DNG has a protective effect on the endometrium and the cycle stability is achieved with 2 to 3 mg DNG; the anti-estrogenic effect on the cervical mucus supports the contraceptive efficacy; no relevant anti-estrogenic effect on vaginal epithelium is reported, while there is an anti-proliferative effect on endometriosis tissue.

In a prospective randomized study, the effect of E2-only therapy was compared to a combined E2/progestin treatment, regarding the excretion of vasoactive mediators, surrogating a possible effect on the vascular system. The progestin used was DNG, while the estrogen was E2V.

Twenty-five women received E2V (2 mg/day) for 3 months and 27 women were treated with E2V (2 mg/day) combined with DNG (2 mg/day) in a continuing regimen.
E2V alone significantly increases the excretion of cyclic guanosine monophosphate (cGMP) and serotonin, suggesting vasodilating effects. Furthermore, the prostacyclin/thromboxane ratio, known to be crucial for the relationship between vasorelaxation and vasoconstriction, increased as well. No significant changes were found for urodilatin, which is known to elicit different effects on the cardiovascular and renal systems, respectively.20

Combined E2V/DNG therapy also led to significant increases in cGMP and serotonin excretion, suggesting that progestin addition for 3 months does not affect these markers. However, in contrast to estrogen-only treatment, there was no significant increase in the prostacyclin/thromboxane ratio, which can be explained by the antagonistic action of the progestin. The excretion of urodilatin significantly increased, probably due to the counterbalancing progestin effects on the renal vascular system.20 In conclusion, the changes in vasoactive markers suggest a potential estrogenic vasorelaxant effect. Since there were no significant differences between the two groups, possible vascular effects of DNG, evaluated for the first time, might not be of clinical relevance, at least not on women without cardiovascular diseases.20

Interactions
Two studies21 investigated the effects of CYP3A4 induction (study 1; E2V/DNG on days 1 to 17, rifampicin 600 mg on days 12 to 16 [n = 16]) and inhibition (study 2; E2V/DNG on days 1 to 14, ketoconazole 400 mg or erythromycin 500 mg 3 times daily on days 8 to 14 [n = 24]) on the pharmacokinetic profiles of E2 and DNG in healthy post-menopausal women. With rifampicin, the geometric mean ratios (day 17 vs 11) of E2 AUC (0 to 24 hours) and Cmax were 56% (90% CI 53.3% to 59.8%) and 75% (66.9%–84.4%), respectively. The corresponding ratios for DNG were 17% (15.6% to 18.7%) and 48% (44.6% to 51.6%), respectively. With ketoconazole, the geometric mean ratios (day 14 vs 7) of E2 AUC (0 to 24 hours) and Cmax were 157% (145% to 171%) and 165% (149% to 182%), respectively. The corresponding ratios for DNG were 286% (263% to 311%) and 194% (184% to 205%), respectively. With erythromycin, the ratios for E2 were 133% (118% to 150%) and 151% (136% to 168%), respectively, and the ratios for DNG were 162% (146% to 180%) and 133% (123% to 144%), respectively. Therefore, there is a significant interaction between inducers and inhibitors of CYP3A4 activity and E2V/DNG.21

Efficacy
Inhibition of ovulation
Natural E2 has proved to be unsatisfactory in respect to cycle control. To investigate this aspect, two randomized, open label, Phase II studies were carried out with the purpose of identifying the optimal dose of E2V and DNG, as well as the duration of their intake during a 28-day cycle.

The first study compared two regimens (regimens 1A and 2A)22 with similar dosages of DNG, but with a different duration of administration. Having established in the first
Combined dienogest/estradiol valerate contraceptive pill

study that the duration of application of regimen 2A was most suitable, but that the dosages of DNG were too low for effective ovulation inhibition, a second study, comparing two regimens (regimens 2B and 2C) with similar duration of treatment, but with increased dosages of DNG, was undertaken.22

Indeed, as DNG does not contain any ethinyl group, the absence of this inhibitory mechanism could explain the relatively short half-life and the higher dose necessary for ovulation inhibition of DNG compared to, for example, levonorgestrel (LNG).31

Both studies were carried out to evaluate ovulation inhibition, which was assessed by transvaginal ultrasound monitoring of follicle size and analysis of serum E2 and progesterone levels, and classified according to the 6-point scoring system of Hoogland and Skouby.24

The primary efficacy end point in both studies was the proportion of women with a Hoogland score of 5 (luteinized unruptured follicle) or a Hoogland score of 6 (ovulation) at cycle 2.22 A Hoogland score of 6 is defined as a ruptured follicle-like structure (FLS) of 13 mm with serum progesterone of 5 nmol/L and E2 of 0.1 nmol/L. A Hoogland score of 5 was considered as critical as a Hoogland score of 6, since a persisting FLS may still develop into a ruptured FLS in subsequent cycles.22

In studies 1 and 2, 192 and 203 women were analyzed, respectively. In study 1, 10 women (10.9%) in regimen 1A and six women (6.4%) in regimen 2A had a Hoogland score of 5 or 6. In study 2, three women (3.1%) in regimen 2B and one woman (1.0%) in regimen 2C had a Hoogland score of 5 or 6. There were no safety concerns with any of the regimens.22

The results of these studies identified a four-phasic oral contraceptive preparation comprising E2V/DNG that provides efficient ovulation inhibition.22

The studies were performed in a stepwise manner in order to determine, firstly, a suitable duration of treatment (study 1) and, secondly, a suitable dose of DNG (study 2) for effective ovulation inhibition.22 Each step increased the ovulation-inhibition potency remarkably, with the result that regimen 2B (with E2V 3 mg in days 1 to 2, E2V 3 mg/DNG 2 mg in days 3 to 7, E2V 2 mg/DNG 3 mg in days 8 to 24 and E2V 1 mg in days 27 to 28) proved to be capable of guaranteeing the best contraceptive efficacy and safety in Phase III studies.22 This formulation contained the lowest dose of DNG that inhibited more than 95% of ovulations in cycle 2.22

A large multicenter study recruited 1377 women for 20 cycles of follow-up. The corrected Pearl Index (PI) for all those entering the study was 0.34, with Qlaira® being equally effective in those over 35 and under 35.25 A further study comparing Qlaira® with a 21/7 20 µg EE/100 µg LNG pill (Miranova®) resulted in just one method failure (in the Miranova® group).7

Nevertheless, Qlaira® has a similar PI to conventional pills and its bleeding pattern in general is similar to that with a 20 µg EE/100 µg LNG pill.25

Bleeding parameters and cycle control

The early estrogen dominance guarantees the initial endometrial proliferation and sensitizes the tissue to the action of progestogens. The Qlaira® regimen with the dominance of DNG in the middle and the later part of the cycle, followed by a moderate estrogenic activity during the final part of the cycle, ensures an acceptable endometrial stability.6 Instead, the use of E2 as a part of a monophasic or a biphasic regimen has a poor cycle control.26–28 In a randomized, double-blind study, E2V/DNG and EE/LNG demonstrated an acceptable bleeding pattern and cycle control, according to several co-primary endpoints, in 798 women aged 18 to 50 years (399 in each treatment group), who received seven cycles of E2V/DNG or EE/LNG.7 The primary efficacy endpoints were the number of days and episodes of bleeding/spotting for a 90-day period, the length of the bleeding/spotting episodes and the incidence and characteristics of scheduled (withdrawal) and unscheduled (intracyclic) bleeding for cycle.7

In particular, withdrawal bleeding was experienced by significantly (P < 0.0001 for each cycle) fewer E2V/DNG recipients (77.7% to 83.2%) than EE/LNG recipients (89.5% to 93.8%) over seven cycles, with a mean absence of withdrawal bleeding in 19.4% (range 16.8% to 22.3%) vs 7.7% (range 6.2% to 10.5%) of women.7 The absence of withdrawal bleeding was experienced at least once over the seven cycles by 56.9% and 37.8% of women receiving E2V/DNG and EE/LNG, with 21.2% and 22.2% experiencing the absence of withdrawal bleeding once and 12.2% and 7.1% experiencing the absence of withdrawal bleeding twice.7 An absence of all withdrawal and intracyclic bleeding occurred in 15.4% and 4.5% of cycles with E2V/DNG and EE/LNG.7 The mean length of withdrawal bleeding was significantly (P < 0.05) shorter in E2V/DNG recipients (4.1 to 4.7 days) than EE/LNG recipients (5.0 to 5.2 days).7 In a descriptive analysis, 56.3% to 62.5% and 37.5% to 43.8% of women in the respective treatment groups experienced ‘spotting’ and/or ‘light bleeding’ (data derived from a graph).7 A significant difference (P-value not reported) in the maximum intensity of withdrawal bleeding was observed between E2V/DNG and EE/LNG therapy; mean maximum intensity withdrawal
bleeding scores were 3.2 to 3.3 per cycle with E2V/DNG and 3.6 per cycle with EE/LNG. From the end of the exposure to the progestogen component, the median onset of withdrawal bleeding was days 2 to 3 with E2V/DNG and day 3 with EE/LNG.9

For instance, no significant difference in the incidence of intracyclic bleeding over seven cycles was observed between the E2V/DNG (10.5% to 18.6% of women) and EE/LNG (9.9% to 17.1%) groups in the double-blind study, with a heavier intensity observed less often with E2V/DNG than with EE/LNG (mean 2.4% vs 4.0% of women).7

Average hemoglobin levels remained unchanged throughout the treatment in both groups.7 There was one unintended pregnancy attributed to method failure, during the treatment in a woman who received EE/LNG.7

In another non-comparative, multicenter study, in which 1391 women were enrolled (1377 comprised the full analysis set and 1074 completed treatment), E2V/DNG demonstrated a high contraceptive efficacy.29 Six of the pregnancies were attributed to method failure, resulting in an adjusted PI, based on 1786.5 women-years of exposure, of 0.34 (upper limit of 95% CI 0.73).29 In a subset of women aged 18 to 35 participating in this study, 12 pregnancies occurred, five of which were attributed to method failure; the unadjusted PI, based on 1277.5 women-years of exposure, was 0.94 (upper limit of 95% CI 1.65), while the adjusted PI, based on 1268.5 women-years of exposure, was 0.40 (upper limit of 95% CI 0.92).29 The Kaplan–Meier estimate of the cumulative pregnancy rate for this subset of women was 0.0142 (95% CI 0.0080 to 0.0251).29

Moreover withdrawal bleeding was generally stable throughout this study, with 76.8% to 81.6% of women experiencing withdrawal bleeding during cycles 1 to 19 of E2V/DNG therapy, although the intensity and duration of withdrawal bleeding progressively decreased with treatment (no data or statistical analysis reported).29

A minority of women experienced intracyclic bleeding in the double-blind7 and non-comparative29 studies.

**Metabolism**

Various hormone parameters and serum-binding globulins were investigated in a double-blind, controlled, randomized, four-arm, bincentric clinical study.30 Four groups with 25 volunteers each, were treated for six cycles with monophasic combination containing 21 tablets with either 30 µg EE + 2 mg DNG, 20 µg EE + 2 mg DNG, 10 µg EE + 2 mg E2V + 2 mg DNG, or 20 µg EE + 100 µg LNG. The DNG-containing oral contraceptives caused a higher increase in SHBG and thyroxine binding globulin (TBG) levels than the LNG-containing preparation. There was a reduction of dehydroepiandrosterone sulfate throughout the study in all treatment groups, which appeared to be enhanced with the increasing length of treatment.30

There was a rise in CBG in all groups, which was most pronounced in women treated with 30 EE/DNG (+90%) and least with EE/E2V/DNG (+55%), indicating a minor hepatic impact of 2 mg E2V compared to 20 or 30 µg EE, and no effect of the progestogen component. It is known that the treatment with low-dose oral contraceptives generally does not influence prolactin levels,31–35 except from a sporadic and transitory hyperprolactinemia in predisposed women.36,37

In contrast to EE, the use of E2V in oral contraceptives seemed to cause a time-dependent significant rise in prolactin levels that was 40% higher after six treatment cycles, while the cycle control was better with the oral contraceptives containing 30 µg EE.30 (Table 1).

Another single center, open-label, randomized controlled trial was performed to compare the metabolic effects of a new four-phasic oral contraceptive comprising E2V and DNG with EE and LNG. Women aged 18 to 50 years received, for seven cycles, a four-phasic regimen containing DNG (2 days E2V 3 mg, 5 days E2V 2 mg/DNG 2 mg, 17 days E2V 2 mg/DNG 3 mg, 2 days E2V 1 mg, 2 days placebo; n = 30) or a sequential regimen of EE and LNG (6 days EE 0.03 mg/LNG 0.05 mg, 5 days EE 0.04 mg/LNG 0.075 mg, 10 days EE 0.03 mg/LNG 0.125 mg, 7 days placebo; n = 28).38 The main efficacy variable was the individual-specific relative variation in high-density lipoprotein and low-density lipoprotein cholesterol from baseline to cycle 7.38 Hemostatic parameters, carbohydrate metabolism and hormone levels were also investigated.38 The change in high-density lipoprotein cholesterol was +7.9% ± 21.8% for women using E2V and DNG and −2.3% ± 14.4% for EE and LNG (P = 0.055). The corresponding changes for low-density lipoprotein cholesterol were −6.5% ± 15.9% and −3.0% ± 17.4%, respectively (P = 0.458).38 In general, variations in hemostatic features were less pronounced with E2V and DNG than with EE and LNG.38 The carbohydrate metabolism pattern remained unchanged and within the normal limits in both groups. SHBG levels increased by +62.7% ± 50.5% and +111.6% ± 48.0% for women using E2V and DNG, compared to EE and LNG, respectively.38 Oral contraceptive containing E2V and DNG demonstrated a more favorable effect on lipid profiles and had a slight impact on hemostatic parameters compared with EE and LNG. No clinically important changes in metabolic features were observed in both treatment groups38 (Table 2).
One of the most relevant complications of oral contraceptive use is thromboembolic disease, and the relative risk of deep vein thrombosis (DVT) rises especially during the first year of use, suggesting an important role of predisposition and risk factors.39–42 Nevertheless, DVT is a rare event in young women, and consequently fairly reliable epidemiological findings cannot be expected before new formulations have been used by a large number of women for a sufficient period of time. As a surrogate, regulatory authorities require controlled studies on the effect of new oral contraceptive formulations or regimens on hemostatic parameters, even though no causal relationship has so far been established between oral contraceptive-induced changes in distinct hemostatic parameters and the risk of venous thromboembolic events (VTEs).43

The decrease in the incidence of VTEs after introduction of low-dose oral contraceptives containing ≤35 µg EE suggested a causal association with the estrogen dose.39,44–46 This might be possible because changes in coagulation and fibrinolysis cascade were significantly lower with 30 µg EE containing COs than with 50 µg EE.47 Therefore, development of new oral contraceptive formulation was characterized by a reduction in EE dose to ≤20 µg, which had to be compensated by more potent progestins, in order to maintain the contraceptive efficacy.13

In an open-label study,38 Qlaira® was compared with Logynon® (triphasic EE/LNG oral contraceptives) in terms of plasma lipids and hemostatic parameters over seven cycles. It was found that levels of prothrombin fragment 1 + 2, and D-dimer remained relatively unchanged with E2V/DNG. In a further open-label crossover study,48 women aged 18 to 50 years were randomized to receive the four-phasic oral contraceptive containing E2V/DNG or a monophasic oral contraceptive containing EE 0.03 mg/LNG 0.15 mg, in order to compare the hemostatic effects. Women received each treatment for three cycles, with two washout cycles between treatments. The primary efficacy variables were the intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle 3. Secondary efficacy variables included the intra-individual absolute changes in procoagulatory and anticoagulatory parameters from baseline to cycle 3. Data from 29 women were assessed. Overall, changes in hemostatic parameters from baseline to cycle 3 were generally less evident with E2V/DNG than with EE/LNG.48 The intra-individual absolute change in prothrombin fragment 1 + 2 was +0.00 ± 0.04 nmol/L with E2V/DNG, compared with +0.03 ± 0.16 nmol/L with EE/LNG (P = 0.43). The intra-individual absolute change in D-dimer with E2V/DNG was +38.9 ± 129.9 ng/mL, which was significantly lower (P = 0.01) than the change with EE/LNG (+157.9 ± 198.3 ng/mL).48 The intra-individual absolute change in prothrombin (factor II) was less pronounced with E2V/DNG (+10.4% ± 17.5%) vs EE/LNG (+24.0% ± 13.0%).48 Changes in procoagulatory parameters were generally less pronounced with E2V/DNG than with EE/LNG.48 The intra-individual absolute change in fibrinogen

---

### Table 1 Metabolic changes from E2V/DNG compared to EE/DNG and EE/LNG

| Oral contraceptives | 30 µg EE/2 mg DNG | 20 µg EE/2 mg DNG | 10 µg EE/2 mg E2V/2 mg DNG | 20 µg EE/100 mg LNG |
|--------------------|------------------|------------------|--------------------------|-------------------|
| SHBG               | ++               | ++               | ++                       | +                 |
| TBG                | ++               | ++               | ++                       | +                 |
| DHEAS              | − −              | − −              | − −                      | − −               |
| CBG                | +++              | ++               | +                        | ++                |
| PRL                | stable           | stable           | ++                       | stable            |

**Table 2 Metabolic change from E2V/DNG compared to EE/LNG**

| Oral contraceptives | E2V/DNG | EE/LNG | P value |
|---------------------|---------|--------|---------|
| HDL                 | +7.9 ± 21.8% | −2.3 ± 14.4% | 0.055 |
| LDL                 | −6.5 ± 15.9% | −3.0 ± 17.4% | 0.458 |
| SHBG                | 62.7 ± 50.5% | 111.6 ± 48% | −       |
| Prothrombin fragment 1 + 2 | stable | stable | −       |
| D-dimer             | stable   | stable  | −       |

**Abbreviations:** E2V, estradiol valerate; DNG, dienogest; EE, ethinylestradiol; LNG, levonorgestrel; SHBG, sex hormone binding globulin; DHEAS, dehydroepiandrosterone sulfite; CBG, cortisol binding globulin; PRL, prolactin.

---

Coagulation disorders

One of the most relevant complications of oral contraceptive use is thromboembolic disease, and the relative risk of deep vein thrombosis (DVT) rises especially during the first year of use, suggesting an important role of predisposition and risk factors.39–42 Nevertheless, DVT is a rare event in young women, and consequently fairly reliable epidemiological findings cannot be expected before new formulations have been used by a large number of women for a sufficient period of time. As a surrogate, regulatory authorities require controlled studies on the effect of new oral contraceptive formulations or regimens on hemostatic parameters, even though no causal relationship has so far been established between oral contraceptive-induced changes in distinct hemostatic parameters and the risk of venous thromboembolic events (VTEs).43

The decrease in the incidence of VTEs after introduction of low-dose oral contraceptives containing ≤35 µg EE suggested a causal association with the estrogen dose.39,44–46 This might be possible because changes in coagulation and fibrinolysis cascade were significantly lower with 30 µg EE containing COs than with 50 µg EE.47 Therefore, development of new oral contraceptive formulation was characterized by a reduction in EE dose to ≤20 µg, which had to be compensated by more potent progestins, in order to maintain the contraceptive efficacy.13

In an open-label study,38 Qlaira® was compared with Logynon® (triphasic EE/LNG oral contraceptives) in terms of plasma lipids and hemostatic parameters over seven cycles. It was found that levels of prothrombin fragment 1 + 2, and D-dimer remained relatively unchanged with E2V/DNG. In a further open-label crossover study,48 women aged 18 to 50 years were randomized to receive the four-phasic oral contraceptive containing E2V/DNG or a monophasic oral contraceptive containing EE 0.03 mg/LNG 0.15 mg, in order to compare the hemostatic effects. Women received each treatment for three cycles, with two washout cycles between treatments. The primary efficacy variables were the intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle 3. Secondary efficacy variables included the intra-individual absolute changes in procoagulatory and anticoagulatory parameters from baseline to cycle 3. Data from 29 women were assessed. Overall, changes in hemostatic parameters from baseline to cycle 3 were generally less evident with E2V/DNG than with EE/LNG.48 The intra-individual absolute change in prothrombin fragment 1 + 2 was +0.00 ± 0.04 nmol/L with E2V/DNG, compared with +0.03 ± 0.16 nmol/L with EE/LNG (P = 0.43). The intra-individual absolute change in D-dimer with E2V/DNG was +38.9 ± 129.9 ng/mL, which was significantly lower (P = 0.01) than the change with EE/LNG (+157.9 ± 198.3 ng/mL).48 The intra-individual absolute change in prothrombin (factor II) was less pronounced with E2V/DNG (+10.4% ± 17.5%) vs EE/LNG (+24.0% ± 13.0%).48 Changes in procoagulatory parameters were generally less pronounced with E2V/DNG than with EE/LNG.48 The intra-individual absolute change in fibrinogen
was +0.3 ± 1.5 g/L with E2V/DNG vs +0.8 ± 1.1 g/L with EE/LNG. Corresponding values for factor VII activity were +2.3% ± 17.2% and +6.8% ± 14.2%, respectively. Almost no variation in Factor VIII activity was observed with either E2V/DNG (−1.3% ± 12.9%) or EE/LNG (+2.6% ± 12.2%).

Changes in anticoagulatory parameters were minimal, but tended to be less pronounced with E2V/DNG than with EE/LNG. Antithrombin III activity remained stable with E2V/DNG and EE/LNG, with the intra-individual absolute change being −0.3% ± 6.5% and −3.0% ± 6.7%, respectively. Changes in protein C and protein S activity were minimal with E2V/DNG (−2.3% ± 14.1% and +4.5% ± 11.0%, respectively) and EE/LNG (+5.7% ± 13.6% and −0.8% ± 20.6%, respectively). Activated protein C (APC) resistance remained unchanged during the treatment with E2V/DNG (−0.04 ± 0.28) and EE/LNG (−0.08 ± 0.40). Almost no change was registered in APC sensitivity with E2V/DNG (+0.09 ± 0.43), but a slight increase with EE/LNG (+0.6 ± 0.7). Indeed, the innovative four-phasic oral contraceptive composed of E2V/DNG was well-tolerated and had less pronounced effects on hemostatic parameters than a monophasic oral contraceptive composed of EE/LNG.

These findings are consistent with those observed in a study comparing E2V/DNG with a triphasic regimen of EE/LNG, suggesting that E2V/DNG has a minor impact on hemostatic parameters compared with EE/LNG (Table 3).

A specific study was carried out to investigate the effect of an oral contraceptive containing 30 μg EE and 2 mg DNG with two different regimens on various hemostatic parameters. Hemostatic parameters were measured in 59 women treated with a monophasic oral contraceptive containing 30 μg EE + 2 mg DNG either conventionally (13 cycles with 21 days of treatment + 7 days without hormones) or with an extended-cycle regimen (four extended cycles with 84 days of continuous administration of EE/DNG + 7 days without hormones). Blood samples were taken on days 21 to 26 of the previous control cycle and on days 19 to 21 of the 3rd and 13th conventional cycle, or on days 82 to 84 of the first and fourth extended cycle. After 3 and 12 months, important increases in fibrinogen (20%), factor VII antigen (50% to 60%), factor VII activity (45%), activated factor VII (30% to 45%) and factor VIII activity (10% to 20%) took place in both treatment regimens. In both groups, there was a slight but significant fall in the level and activity of antithrombin, a 20% to 25% decrease in total and free protein S and a 15% to 20% increment in the level and activity of protein C, but no relevant variation of the thrombin–antithrombin complex. A significant rise over time of about 25% of prothrombin fragment 1 + 2 occurred only in the extended-cycle group, but this effect did not change significantly from that observed during conventional treatment. Plasminogen increased by 50% in both groups, while tissue-plasminogen activator (t-PA) activity rose by 15% in the conventional group and by 25% to 30% in the extended-cycle group. In both groups, t-PA antigen was diminished by about 30% and plasminogen activator inhibitor (PAI)-1 by 40% to 60%. The levels of the plasmin–antiplasmin complex increased by 30% to 40% and those of D-dimers by 20% to 55%. The prothrombin time was slightly increased and the activated partial thromboplastin time was slightly decreased.

This study clearly demonstrated that there is no significant difference between the conventional and the extended-cycle regimen with respect to any hemostatic parameters at any time, during treatment with EE/DNG.

This is the first double-blind, controlled, randomized study to compare the effect of different estrogen components in oral contraceptives on hemostatic parameters. Four groups of 25 women each were treated for six cycles with monophasic combinations containing 21 tablets with either 30 μg EE + 2 mg DNG, 20 μg EE + 2 mg DNG, 10 μg EE + 2 mg E2V + 2 mg DNG, or 20 μg EE + 100 μg LNG. Blood samples were taken on days 21 to 26 of the control cycle and on days 18 to 21 of the first, third and sixth treatment cycle. Treatment with all four oral contraceptives provoked an increase in fibrinogen levels, prothrombin fragment 1−2, D-dimer, plasminogen, and plasmin-antiplasmin complex and protein C activity, a lower antithrombin activity, t-PA and PAI, and a small decrease in the sensitivity to activated protein C, but no relevant change.

### Table 3 Hemostatic parameters change from E2V/DNG compared to EE/LNG

| Oral contraceptive | E2V/DNG | EE/LNG |
|--------------------|---------|--------|
| Prothrombin fragment 1 + 2 | +0.00 ± 0.04 nmol/L | +0.03 ± 0.16 nmol/L |
| D-dimer | +38.9 ± 129.9 ng/mL | +157.9 ± 198.3 ng/mL |
| Prothrombin | +10.4 ± 17.5% | +24 ± 13% |
| Fibrinogen | +0.3 ± 1.5 g/L | +0.8 ± 1.1 g/L |
| Factor VII | +2.3 ± 17.2% | +6.8 ± 14.2% |
| Factor VIII | −1.3 ± 12.9% | +2.6 ± 12.2% |
| Antithrombin III | −0.3 ± 6.5% | −3.0 ± 6.7% |
| ProC | −2.3 ± 14.1% | +5.7 ± 13.6% |
| ProS | +4.5 ± 11.0% | −0.8 ± 20.6% |
| APC | −0.04 ± 0.28 | −0.08 ± 0.40 |
| APC sensitivity | +0.09 ± 0.43 | +0.6 ± 0.7 |

**Abbreviations:** E2V, estradiol valerate; DNG, dienogest; EE, ethinylestradiol; LNG, levonorgestrel; APC, activated protein C.
in the thrombin–antithrombin complex. The results, which revealed a rise in protein C activity by 10% to 15% of women during use of all four formulations, are in accordance with findings of previous oral contraceptive studies.\textsuperscript{16,49–58} The effects of EE/E2V/DNG on total and free protein S and on t-PA and PAI were lower compared to 20 µg EE + 2 mg DNG effects, suggesting that the impact of 2 mg E2V on several hemostatic parameters is not as much that of 10 µg EE. The fall of total and free protein S observed in the present study with the DNG-containing oral contraceptives was also in the range of the results of previous studies.\textsuperscript{39–61}

The results show an antagonistic effect of LNG on the EE-induced rise of factor VII activity and fragment 1 + 2 and on the EE-dependent reduction of total and free protein S.\textsuperscript{13}

In the previous study, no significant differences between the four formulations were observed in their effect on most hemostatic parameters, except those on total and free protein S, and on factor VII in cycle 6. In fact, total and free protein S decreased according to the EE dose during treatment with oral contraceptives containing DNG, and the effect of EE/E2V/DNG was less compared to that of 20 EE/DNG. The results suggest that 10 µg EE combined with DNG exerts a stronger effect on some hemostatic parameters than 2 mg E2V.\textsuperscript{13}

**Safety**

**Adverse events and tolerability**

A randomized comparative trial\textsuperscript{7} reported adverse reactions in 10.0% and 8.5% of women receiving E2V/DNG and EE/LNG, respectively. The most common adverse events were breast pain, headache, acne, alopecia, migraine and an increase of bodyweight.\textsuperscript{7} The most frequent adverse events in women treated with E2V/DNG were breast pain (3.8%), headache (2.5%), and vaginal infection (2.5%), while the most frequently reported adverse events in women treated with EE/LNG were acne (3.3%), headache (3.3%), and nasopharyngitis (1.8%). The incidence of dysmenorrhea in the preceding 6 months was 9.5% in the E2V/DNG group, and 6.8% in the EE/LNG group, but during the study, the reported incidence of dysmenorrhea was 0.5% in both treatment groups.\textsuperscript{7}

The frequency (10.0% vs 8.5%) and nature of treatment-related adverse events was generally similar between the E2V/DNG and EE/LNG treatment groups.\textsuperscript{7} Serious adverse events occurred in four E2V/DNG recipients and three EE/LNG recipients. None of the serious adverse events reported were deemed to be related to the study medication, apart from a ruptured ovarian cyst, autonomic nervous system imbalance (one E2V/DNG recipient) and breast cancer (one EE/LNG recipient).\textsuperscript{7} No deaths were reported.\textsuperscript{7}

Endrikat et al\textsuperscript{22} reported only one serious adverse event in a woman in study 1 (regimen 1A) considered possibly treatment related (ovarian cyst). No deaths occurred during the studies.\textsuperscript{22} In study 1, four women had adverse events considered possibly related to treatment that resulted in study discontinuation (regimen 1A, n = 2 [ovarian cyst, breast pain]; regimen 2A, n = 2 [edema, diarrhea]).\textsuperscript{22} Eight women in study 2, had treatment-related adverse events that resulted in discontinuation of treatment (regimen 2B, n = 5 [depression, headache, worsening acne, eye irritation, furunculosis]; regiment 2C, n = 3 [emotional liability, n = 2, headache]).\textsuperscript{22}

In the non-comparative study, treatment-related adverse events occurred in 272 women (19.8%).\textsuperscript{29}

The most frequently reported treatment-emergent adverse events in women aged 18 to 50 years in the pooled analysis (n = 2266) were breast discomfort (4.9% of women), metrorrhagia (4.9%) and headache (3.1%).\textsuperscript{62} Other treatment-emergent adverse events occurring in ≥1% of women included acne (2.8% of women), increase in bodyweight (1.5%), amenorrhea (1.7%), dysmenorrhea (1.7%) and abdominal pain (1.7%).\textsuperscript{62}

In the study by Parke et al,\textsuperscript{48} the proportion of women reporting adverse events was generally similar in both treatment groups. No adverse events were rated as serious.\textsuperscript{48}

**Satisfaction**

In the open-label 20-cycle study (n = 1377), 79.5% of women were either satisfied or very satisfied with Qlaira\textsuperscript{®}, and just over two-thirds of the full analysis set would consider taking Qlaira\textsuperscript{®} in the future. Only 7.4% were dissatisfied or very dissatisfied. One hundred and forty-two women complained because of adverse events but only 37 discontinued use because of irregular menstrual bleeding.\textsuperscript{29}

In the study by Ahrendt et al,\textsuperscript{7} 79.4% of women were satisfied with E2V/DNG and 79.9% with EE/LNG; 39.8% of women were very satisfied with E2V/DNG and 35.3% of women were very satisfied with EE/LNG.

**Contraindications**

E2V/DNG is contraindicated only in women with an acquired or hereditary predisposition for arterial or venous thrombosis; a history of or current episodes of arterial thrombosis, cerebrovascular accident, liver cancer, pancreatitis (if associated with severe hypertriglyceridemia), severe hepatic disease or venous thrombosis; a history of migraine with focal neurological symptoms; hypersensitivity to the active substances or to any of the excipients; known or suspected sex-steroid influenced cancer; the presence of
severe or multiple arterial or venous thrombosis risk factors, including diabetes mellitus with vascular symptoms, severe dyslipoproteinemia and severe hypertension or undiagnosed vaginal bleeding.3

Discussion
The dose of EE has been progressively reduced over time, and contraceptives containing 20 µg or even 15 µg of EE are currently available. However, EE dose will be unlikely to be further reduced, due to the possible occurrence of symptoms of low estrogen levels.63 Furthermore, some studies have suggested that a daily dose of 10 µg may have unfavorable impact on hemostatic parameters.14 The objective was to develop hormonal contraceptives containing natural estrogens like E2, which is structurally identical to endogenous estradiol.

DNG was included as the progestin component, as it is known to have a relevant protective function on the endometrium,64 it is well tolerated and associated with excellent contraceptive efficacy when combined with EE.65–68 However, previous attempts to replace EE with E2 proved to be somewhat unsatisfactory with respect to cycle control,26–28 particularly when E2 was administered as part of a monophasic or a biphasic regimen. Therefore, previous studies, which were carried out in an iterative stepwise manner, have shown that the current regimen (E2V 3 mg for 2 days, followed by E2V/DNG 2 mg/2 mg for 5 days, E2V/DNG 2 mg/3 mg for 17 days, E2V 1 mg for 2 days and placebo for 2 days) contains the optimal dose of DNG necessary for efficient ovulation inhibition when combined with E2V.7 The dynamic dosing regimen was designed to ensure estrogen dominance in the first part of the cycle and progestin dominance in the middle to the later part of the cycle, thereby optimizing the bleeding pattern. Early estrogenic dominance is hypothesized to ensure initial endometrial proliferation and severity for mid-cyclical progestin action and endometrial stroma stability, particularly towards the end of the cycle.7

Women who received E2V/DNG have fewer bleeding/spotting days and fewer bleeding/spotting episodes than women who received EE/LNG; accordingly, an absence of withdrawal bleeding in cycles 1 to 7 occurred more often in women treated with E2V/DNG than with EE/LNG. Over seven cycles of treatment, the mean length of withdrawal bleeding was slightly shorter in women treated with E2V/DNG compared with women treated with EE/LNG; and the maximum intensity of withdrawal bleeding was more often spotting and light bleeding in women treated with E2V/DNG. Conversely, the maximum intensity of withdrawal bleeding was more often normal or heavy in women treated with EE/LNG.7 The oral contraceptive composed of E2V/DNG is comparable to EE-containing oral contraceptive in terms of bleeding profile.7 Indeed, E2V/DNG showed an acceptable bleeding pattern and level of cycle control.

This novel oral contraceptive containing E2V and DNG is effective and well-tolerated,31 delivers stable levels of E2 throughout the cycle65 and is associated with a reduced impact on hemostatic and metabolic parameters compared with EE/LNG.7,38

In users of the DNG-containing oral contraceptives, the reduction in total and free protein S, and in t-PA and PAI activity was elevated, but not significantly different from that with EE/LNG.13 The levels of high-density lipoprotein cholesterol increased, while the levels of prothrombin fragment 1 + 2 and D-dimer remained relatively unchanged; in contrast, the levels of SHBG, CBG and TBG increased.38

The finding that Qlaira® has a reduced metabolic impact when compared to EE/LNG-containing oral contraceptives, may attract particularly women aged over 35 years old or women with uncomplicated diabetes. Qlaira® may be very suitable also for women complaining of “estrogen withdrawal symptoms” such as headache or mood changes, because about 20% of women each month have no withdrawal bleed using Qlaira®.25

The Qlaira® regimen provides reliable contraceptive efficacy7,29 and has been shown to be well tolerated,29 with stable serum E2 levels maintained throughout the cycle.65

In fact, about 79.4% of women were satisfied with E2V/DNG.7,29

We have no data on the efficacy and tolerability of E2V/DNG in adolescents aged < 18 years.3

Conclusion
The previous attempts to use natural estrogens, such as E2, for hormonal contraception were unsatisfactory in terms of cycle control because of the use of suboptimal doses of E2 and of the inappropriate ratio of estrogen to progestin. The natural E2 and the progestin DNG have been combined in a unique dynamic dosing regimen with four hormonal dosage steps in which estrogen and progestin doses follow as closely as possible the menstrual cycle physiology. E2V/DNG is the best combination to guarantee a good control of the menstrual cycle, together with high contraceptive safety, high tolerability and a reduced metabolic impact.
Disclosure

The authors declare no conflicts of interest.

References

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data. 2004;350:1–36.
2. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol. 1988;158:1646–1652.
3. Emc.Medicine.org [homepage on the Internet]. Qlaira® – Summary of product Characteristics (SPC). Bayer Schering Pharma. http://emc.medicines.org.uk/medicine/21700/SPC/Qlaira®/. Accessed November 17, 2009.
4. Loose DS, Stancel GM. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2005. p. 1541–1571.
5. Graziottin A. Che cosa vogliono le donne nella contracezione. Che cosa può offrire Klaira. Contracezione Fertilità Sexualità. Numero speciale. 2009;36:23–28.
6. Nappi RE. Profilo farmacologico di Qlaira®. Contracezione Fertilità Sexualità. Numero speciale. 2009;36:5–10.
7. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–444.
8. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dieno- gest. Eur J Contracept Reprod Health Care. 2009;14(3):221–232.
9. Oettel M, Graser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today (Barc). 2001;37:3–15.
10. Mueck AO, Seeger H. Pharmacology of dienogest. Gynecol Obstet Invest. 2009;14:9–12.
11. Zimmerman H, Thebault JJ, Duvauchelle T, et al. Pharmacokinetics of estradiol valerate 2 mg + dienogest 2 mg after single and repeated oral administration in healthy postmenopausal women. Clin Drug Invest. 2000;20:123–134.
12. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–518.
13. Wiegartz I, Lee JH, Kutscheria E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70(2):97–106.
14. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Sillverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 1989;61(1):65–69.
15. Helgason S. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand Suppl. 1982;107:1–29.
16. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003;67(3):173–185.
17. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24(1–2):1–19.
18. Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179(3 Pt 2):S51–S61.
19. Norris L, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103(3):261–267.
20. Mueck AO, Seeger H, Lüdtke R, Graser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas. 2001;38(3):305–313.
21. Blode H, Schott B, Rohde M, Kunz M, Zuev S, editors. Effects of CY34A induction and inhibition on the pharmacokinetics of estradiol valerate/dienogest. Proceedings of the 11th world congress on controversies in obstetrics gynecology and infertility; 2008 Nov. p. 27–30; Paris, France.
22. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers J, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78(3):218–225.
23. Moore C, Feichtinger W, Klinger G, et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs Today (Barc). 1999;35 Suppl C:53–68.
24. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47(6):583–590.
25. Mansour D. Qlaira®: a natural change of direction. J Fam Plann Reprod Health Care. 2009;35(3):139–142.
26. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception. Contraception. 1980;21(5):445–459.
27. Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-ocyl acetate and desogestrel. Acta Obstet Gynecol Scand. 1987;66(6):543–547.
28. Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet. 1979;2(8140):471–472.
29. Nahum GG, Parke S, Wildt L, et al. Efficacy and tolerability of a new oral contraceptive containing estradiol and dieno- gest [abstract]. Obstet Gynecol. 2008;111 Suppl 4:S15. Poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3–7; New Orleans, LA.
30. Wiegartz I, Kutscheria E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67(1):25–32.
31. Refn H, Kjaer A, Lebecch AM, Borggaard B, Sierup L. Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1990;41(3):259–269.
32. Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception. 1993;47(1):55–68.
33. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983;27(6):577–590.
34. Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58(2):75–81.
35. Kuhl H, Gahn G, Romberg G, März W, Taubert HD. A random- ized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception. 1985;31(6):583–593.
36. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters. Contraception. 1988;38(6):593–603.
37. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol. 1985;65(4):506–510.
38. Parke S, Nahum GG, Mellingler U, Junge W. Metabolic effects of a new 4-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting; 2008 May 3–7; New Orleans, LA. Obstet and Gynecol. 2008;111 Suppl 4:125.

39. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: status of the art. World Health Organization. Hum Reprod. 1998;13(11):2981–2983.

40. Herings RM, Urrutqui J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354(9173):127–128.

41. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160(1):49–52.

42. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65(3):187–196.

43. Wiegratz I, Stahlberg S, Manthey T, et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception. 2008;78(5):384–391.

44. Meade TW. Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol. 1996;53(2):75–84.

45. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Meade TW. Oral contraceptives, clotting factors, and thrombosis. Am J Epidemiol. 1982;142(6 Pt 2):758–761.

46. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and thromboembolic disease. Am J Epidemiol. 1991;133(1):32–37.

47. Sabra A, Bonnar J. Hemosatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. J Reprod Med. 1983;28 Suppl 1:S85–S91.

48. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 1993;306(6883):956–963.

49. Sabra A, Bonnar J. Hemosastic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. J Reprod Med. 1983;28 Suppl 1:S85–S91.

50. Parke S, Junge W, Mellingler U, Duijkers I, Klipping C. Comparative effects of four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters. Proceeding of the 24th Annual Meeting of the ESHRE; 2008 July 7–9; Barcelona, Spain.

51. Guida et al. International Journal of Women's Health

Publish your work in this journal

The International Journal of Women's Health is an international, peer-reviewed open-access journal publishing original research, reports, reviews and comments on all aspects of women's healthcare including gynecology, obstetrics, and breast cancer. Subject areas include: Chronic conditions (migraine headaches, arthritis, osteoporosis);

Submit your manuscript here: http://www.dovepress.com/international-journal-of-womens-health-journal

Dovepress

Endocrine and autoimmune syndromes; Sexual and reproductive health; Psychological and psychosocial conditions. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.